EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING

被引：0
|
作者：
Capehorn, M. [1 ]
Hallen, N. [2 ]
Hunt, B. [3 ]
机构：
[1] Rotherham Inst Obes, Rotherham, S Yorkshire, England
[2] Novo Nordisk AS, Soborg, Denmark
[3] Ossian Hlth Econ & Commun, Basel, Switzerland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB42
引用
收藏
页码：S512 / S512
页数：1
相关论文
共 50 条
  • [31] Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
    Peter Gæde
    Pierre Johansen
    Christian Klyver Tikkanen
    Richard Fulton Pollock
    Barnaby Hunt
    Samuel Joseph Paul Malkin
    Diabetes Therapy, 2019, 10 : 1297 - 1317
  • [32] Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
    Gaede, Peter
    Johansen, Pierre
    Tikkanen, Christian Klyver
    Pollock, Richard Fulton
    Hunt, Barnaby
    Malkin, Samuel Joseph Paul
    DIABETES THERAPY, 2019, 10 (04) : 1297 - 1317
  • [33] Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes
    Zupa, Margaret F.
    Codario, Ronald A.
    Smith, Kenneth J.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (15) : 1133 - 1141
  • [34] Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11
    Evans, Marc
    Chubb, Barrie
    Malkin, Samuel J. P.
    Berry, Sasha
    Lawson, Jack
    Hunt, Barnaby
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 491 - 500
  • [35] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Ataru Igarashi
    Barnaby Hunt
    Lars Wilkinson
    Jakob Langer
    Richard F. Pollock
    Advances in Therapy, 2020, 37 : 4446 - 4457
  • [36] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Igarashi, Ataru
    Hunt, Barnaby
    Wilkinson, Lars
    Langer, Jakob
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2020, 37 (10) : 4446 - 4457
  • [37] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
    Malkin, Samuel J. P.
    Russel-Szymczyk, Monika
    Liidemann, Girtel
    Volke, Vallo
    Hunt, Barnaby
    DIABETES THERAPY, 2019, 10 (01) : 159 - 176
  • [38] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
    Samuel J. P. Malkin
    Monika Russel-Szymczyk
    Girtel Liidemann
    Vallo Volke
    Barnaby Hunt
    Diabetes Therapy, 2019, 10 : 159 - 176
  • [39] The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
    Malkin, Samuel J. P.
    Russel-Szymczyk, Monika
    Psota, Marek
    Hlavinkova, Lucia
    Hunt, Barnaby
    ADVANCES IN THERAPY, 2019, 36 (08) : 2034 - 2051
  • [40] Once-weekly semaglutide vs existing once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of Type 2 diabetes: Long-term cost-effectiveness analyses in the UK setting
    Viljoen, A.
    Hoxer, C. S.
    Johansen, P.
    Malkin, S. J. P.
    Hunt, B.
    Bain, S. C.
    DIABETIC MEDICINE, 2019, 36 : 134 - 134
12345